Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

533 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Truncated FGFR2 is a clinically actionable oncogene in multiple cancers.
Zingg D, Bhin J, Yemelyanenko J, Kas SM, Rolfs F, Lutz C, Lee JK, Klarenbeek S, Silverman IM, Annunziato S, Chan CS, Piersma SR, Eijkman T, Badoux M, Gogola E, Siteur B, Sprengers J, de Klein B, de Goeij-de Haas RR, Riedlinger GM, Ke H, Madison R, Drenth AP, van der Burg E, Schut E, Henneman L, van Miltenburg MH, Proost N, Zhen H, Wientjens E, de Bruijn R, de Ruiter JR, Boon U, de Korte-Grimmerink R, van Gerwen B, Féliz L, Abou-Alfa GK, Ross JS, van de Ven M, Rottenberg S, Cuppen E, Chessex AV, Ali SM, Burn TC, Jimenez CR, Ganesan S, Wessels LFA, Jonkers J. Zingg D, et al. Among authors: chan cs. Nature. 2022 Aug;608(7923):609-617. doi: 10.1038/s41586-022-05066-5. Epub 2022 Aug 10. Nature. 2022. PMID: 35948633 Free PMC article. Clinical Trial.
Clinical Actionability of Comprehensive Genomic Profiling for Management of Rare or Refractory Cancers.
Hirshfield KM, Tolkunov D, Zhong H, Ali SM, Stein MN, Murphy S, Vig H, Vazquez A, Glod J, Moss RA, Belyi V, Chan CS, Chen S, Goodell L, Foran D, Yelensky R, Palma NA, Sun JX, Miller VA, Stephens PJ, Ross JS, Kaufman H, Poplin E, Mehnert J, Tan AR, Bertino JR, Aisner J, DiPaola RS, Rodriguez-Rodriguez L, Ganesan S. Hirshfield KM, et al. Among authors: chan cs. Oncologist. 2016 Nov;21(11):1315-1325. doi: 10.1634/theoncologist.2016-0049. Epub 2016 Aug 26. Oncologist. 2016. PMID: 27566247 Free PMC article.
Why are there hotspot mutations in the TP53 gene in human cancers?
Baugh EH, Ke H, Levine AJ, Bonneau RA, Chan CS. Baugh EH, et al. Among authors: chan cs. Cell Death Differ. 2018 Jan;25(1):154-160. doi: 10.1038/cdd.2017.180. Epub 2017 Nov 3. Cell Death Differ. 2018. PMID: 29099487 Free PMC article. Review.
SMAD4 is critical in suppression of BRAF-V600E serrated tumorigenesis.
Tong K, Kothari OA, Haro KS, Panda A, Bandari MM, Carrick JN, Hur JJ, Zhang L, Chan CS, Xing J, Gatza ML, Ganesan S, Verzi MP. Tong K, et al. Among authors: chan cs. Oncogene. 2021 Oct;40(41):6034-6048. doi: 10.1038/s41388-021-01997-x. Epub 2021 Aug 27. Oncogene. 2021. PMID: 34453124 Free PMC article.
Autophagy promotes growth of tumors with high mutational burden by inhibiting a T-cell immune response.
Poillet-Perez L, Sharp DW, Yang Y, Laddha SV, Ibrahim M, Bommareddy PK, Hu ZS, Vieth J, Haas M, Bosenberg MW, Rabinowitz JD, Cao J, Guan JL, Ganesan S, Chan CS, Mehnert JM, Lattime EC, White E. Poillet-Perez L, et al. Among authors: chan cs. Nat Cancer. 2020 Sep;1(9):923-934. doi: 10.1038/s43018-020-00110-7. Epub 2020 Sep 18. Nat Cancer. 2020. PMID: 34476408 Free PMC article.
Publisher Correction: Autophagy promotes growth of tumors with high mutational burden by inhibiting a T-cell immune response.
Poillet-Perez L, Sharp DW, Yang Y, Laddha SV, Ibrahim M, Bommareddy PK, Hu ZS, Vieth J, Haas M, Bosenberg MW, Rabinowitz JD, Cao J, Guan JL, Ganesan S, Chan CS, Mehnert JM, Lattime EC, White E. Poillet-Perez L, et al. Among authors: chan cs. Nat Cancer. 2021 Sep;2(9):994. doi: 10.1038/s43018-021-00252-2. Nat Cancer. 2021. PMID: 35121870 No abstract available.
533 results